Literature DB >> 22794681

Chapter 8: Rhinosinusitis.

Mary S Georgy, Anju T Peters.   

Abstract

Rhinosinusitis is defined as inflammation of one or more of the paranasal sinuses and affects ∼16% of the population. Acute rhinosinusitis is defined as symptoms lasting <4 weeks and subacute rhinosinusitis is between 4 and 8 weeks. Chronic rhinosinusitis (CRS) is defined as symptoms lasting >8-12 weeks. CRS is divided into three groups: CRS with nasal polyps, CRS without nasal polyps, and allergic fungal rhinosinusitis. The sinus cavities are lined with pseudostratified ciliated columnar epithelial cells interspersed with mucous goblet cells. Cilia continuously sweep the mucous toward the ostial openings and are important in maintaining the proper environment of the sinus cavities. The frontal, maxillary, and anterior ethmoid sinuses drain into the ostiomeatal unit of the middle meatus. The posterior ethmoid sinuses and superior sphenoid sinuses drain into the sphenoethmoid recess of the superior meatus. Most acute sinus infections are caused by viruses and, therefore, it is not surprising that the majority of patients improve within in 2 weeks without antibiotic treatment. A bacterial infection should be considered if symptoms worsen or fail to improve within 7-10 days. Amoxicillin, trimethoprim-sulfamethoxazole, or doxycycline are first-line therapy. The Joint Task Force on Practice Parameters for Allergy and Immunology suggests assessing response to symptoms after 3-5 days of therapy and continuing for an additional 7 days if there is improvement. Combining an intranasal corticosteroid with an antibiotic reduces symptoms more effectively than antibiotics alone.

Entities:  

Mesh:

Year:  2012        PMID: 22794681     DOI: 10.2500/aap.2012.33.3538

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  6 in total

1.  Current understanding of nasal morphology and physiology as a drug delivery target.

Authors:  Julie D Suman
Journal:  Drug Deliv Transl Res       Date:  2013-02       Impact factor: 4.617

2.  Longitudinal Evaluation of Chronic Rhinosinusitis Symptoms in a Population-Based Sample.

Authors:  Agnes S Sundaresan; Annemarie G Hirsch; Amanda J Young; Jonathan Pollak; Bruce K Tan; Robert P Schleimer; Robert C Kern; Thomas L Kennedy; J Scott Greene; Walter F Stewart; Karen Bandeen-Roche; Brian S Schwartz
Journal:  J Allergy Clin Immunol Pract       Date:  2017-11-10

3.  Accuracy of phenotyping chronic rhinosinusitis in the electronic health record.

Authors:  Joy Hsu; Jennifer A Pacheco; Whitney W Stevens; Maureen E Smith; Pedro C Avila
Journal:  Am J Rhinol Allergy       Date:  2014 Mar-Apr       Impact factor: 2.467

4.  Hypoxia-mediated mechanism of MUC5AC production in human nasal epithelia and its implication in rhinosinusitis.

Authors:  Yoon-Ju Kim; Hyung-Ju Cho; Woo-Chul Shin; Hyun-Ah Song; Joo-Heon Yoon; Chang-Hoon Kim
Journal:  PLoS One       Date:  2014-05-19       Impact factor: 3.240

5.  Galectin fingerprinting in naso-sinusal diseases.

Authors:  Anaëlle Duray; Thibault De Maesschalck; Christine Decaestecker; Myriam Remmelink; Gilbert Chantrain; Jennifer Neiveyans; Mihaela Horoi; Xavier Leroy; Hans-Joachim Gabius; Sven Saussez
Journal:  Oncol Rep       Date:  2014-05-23       Impact factor: 3.906

Review 6.  Cyclamen europaeum extract for acute sinusitis.

Authors:  Anca Zalmanovici Trestioreanu; Ankur Barua; Barak Pertzov
Journal:  Cochrane Database Syst Rev       Date:  2018-05-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.